Protein A-Calicheamicin ADC (CAT#: WJY-0423-LS106)

A: The Protein A-Calicheamicin ADC is composed of Protein A conjugated to the potent cytotoxic agent Calicheamicin. Protein A binds to the Fc region of antibodies, facilitating the targeting and delivery of Calicheamicin to cancer cells via receptor-mediated endocytosis, where it induces DNA damage and cell death.

A: Creative Biolabs offers comprehensive support for researchers using the Protein A-Calicheamicin ADC, including technical consultation on experimental design, optimization of ADC concentration, and troubleshooting. They also provide guidance on selecting appropriate controls and ensuring the specificity of the ADC's cytotoxic effects.

A: Yes, Creative Biolabs offers customization services for the Protein A-Calicheamicin ADC. Researchers can request modifications to the linker, conjugation process, or specific components to suit their experimental needs, allowing for tailored solutions that align with their research objectives.

A: The linker in the Protein A-Calicheamicin ADC plays a critical role in maintaining the stability of the conjugate during circulation in the body. It ensures that Calicheamicin remains attached to Protein A until the ADC is internalized into the target cells. Once inside the cell, the linker is cleaved, releasing Calicheamicin to exert its cytotoxic effects. This design minimizes off-target effects and enhances the specificity and performance of the ADC.

A: Researchers might face challenges such as non-specific binding or insufficient internalization when using the Protein A-Calicheamicin ADC. To mitigate these issues, it is important to optimize experimental conditions, such as adjusting the ADC concentration and incubation times, and to include proper controls in the experimental design. Creative Biolabs provides support to help researchers troubleshoot and overcome these challenges, ensuring successful outcomes in their studies.